Clinical value of AKR1B10 in hepatocellular carcinoma: A systematic review and meta-analysis

Abstract

Background To evaluate the clinical value of Aldo-keto reductase family 1 member B10 (AKR1B10) in the diagnosis and prognosis of hepatocellular carcinoma (HCC). Methods A search of the PubMed, China Biology Medicine, Cochrane, and Embase databases was performed to conduct meta-analyses to evaluate the accuracy of AKR1B10 in diagnosing HCC and to assess the impact on prognosis of patients after curative resection of HCC. Results A total of 12 different cohorts from 11 studies including 2747 HCC patients and 2053 controls showed that the pooled specificity and the pooled sensitivity of AKR1B10 for the diagnosis of HCC were 0.78 (95% CI: 0.69–0.85) and 0.85 (95% CI: 0.77–0.90), respectively. The pooled sensitivity and specificity of serum AKR1B10 for the diagnosis of HCC were 0.80 (95% CI: 0.70–0.86) and 0.87 (95% CI: 0.77–0.93), respectively. The pooled sensitivity and specificity of AKR1B10 in malignant tumor tissue for the diagnosis of HCC were 0.78 (95% CI: 0.61–0.89) and 0.82 (95% CI: 0.69–0.90), respectively. The pooled sensitivity and specificity of AKR1B10 to distinguish HCC from benign liver disease were 0.71 (95% CI: 0.62–0.78) and 0.84 (95% CI: 0.77–0.89), respectively. The sensitivity and specificity of AKR1B10 combined with alpha fetoprotein (AFP) in the diagnosis of HCC were 0.84 (95% CI: 0.79–0.88) and 0.88 (95% CI: 0.73–0.95), respectively. The pooled sensitivity and specificity of AKR1B10 in malignant tumor tissue for the diagnosis of early-stage HCC were 0.85 (95% CI: 0.62–0.95) and 0.88 (95% CI: 0.81–0.93), respectively. A meta-analysis of five studies including 798 patients demonstrated that high AKR1B10 expression in liver malignant tumor was associated with better overall survival in patients with HCC after hepatectomy (HR = 0.54, 95% CI: 0.41–0.72, p < 0.001). Conclusions AKR1B10 exhibits a great clinical value in the diagnosis of HCC, especially for early-stage HCC, with excellent diagnostic accuracy. Furthermore, AKR1B10 expression can predict the prognosis of HCC patients after hepatic resection.

Evaluation The Association of Aldo-Keto Reductase Family 1 Member B10 With Hepatocellular Carcinoma

“…In improved cases there was a statistically significant decrease from 4980 to 2125 after treatment P<0.001). Similarly, Schmitz et al revealed that in HCC patients treated with surgical resection (n = 92) or liver transplantation (n = 76), AKR1B10 overexpression was significantly associated with lower tumor classification, underlying viral hepatitis and cirrhosis (6) Similarly, Wang et al revealed that additional reports of associations between favorable HCC prognosis following surgical resection and higher AKR1B10 expression, are consistent with a dynamic role for this enzyme at different stages of HCC development and progression (22). This study, there was a statistically significant negative correlation between AKR1B10 and the following: spleen size, AFP before and after treatment, AST, Child score, total bilirubin, direct bilirubin, and INR while, statistically significant positive correlation was detected with albumin P <0.001.…”

“…The pooled sensitivity and specificity of AKR1B10 in malignant tumor tissue for the diagnosis of early-stage HCC were 0.85 (95% CI: 0.62-0.95) and 0.88 (95% CI: 0.81-0.93), respectively. A metaanalysis of five studies including 798 patients demonstrated that high AKR1B10 expression in liver malignant tumor was associated with better overall survival in patients with HCC after hepatectomy (22). Thus, concluded that; AKR1B10 exhibits a great clinical value in the diagnosis of HCC, especially for early-stage HCC, with good diagnostic accuracy.…”

AKR1B10 inhibits the proliferation and metastasis of hepatocellular carcinoma cells by regulating the PI3K/AKT pathway

“…Furthermore, HCC is a heterogeneous disease with limited chemoradiotherapy treatment ( 7 ). The 5-year survival rate for patients with early-stage HCC has been reported to exceed 50% ( 2 ). Despite this, HCC has a poor 5-year overall survival rate ( 6 ).…”

“…Hepatocellular carcinoma (HCC), the most common form of liver cancer, is one of the most frequently diagnosed malignant neoplasms worldwide ( 1 , 2 ). In recent decades, HCC has received a significant amount of attention due to the rapid rise in HCC-associated mortality ( 1 , 3 ).…”

“…Aldehyde ketone reductase (AKR) family member B10 (AKR1B10) belongs to the AKR1B subgroup ( 9 ). AKR1B10 is a cytosolic NADPH-dependent reductase, catabolizing various endogenous compounds by catalyzing the corresponding redox reactions ( 2 ). According to recent studies, expression of this enzyme is upregulated in several types of cancer, including adrenocortical ( 10 ), breast ( 11 ), colon ( 12 ), and hepatocellular carcinoma ( 13 , 14 ).…”